Please enable Javascript
mHSPC
Metastatic hormone-sensitive prostate cancer
Advertisement
RAVENS: Analyzing Radium-223 vs SABR for Oligometastatic HSPC
Ana Kiess, MD, PhD
mHSPC
|
November 21, 2024
Ana Kiess, MD, PhD, of Johns Hopkins Medicine, reviews the phase II RAVENS trial on radium-223 with SABR versus SABR alone.
View More
Docetaxel Plus 177Lu Boosts Antitumor Activity in mHSPC Over Docetaxel Alone
Emily Menendez
mHSPC
|
November 19, 2024
The phase II UpFrontPSMA study evaluated the use of [177Lu]Lu-PSMA-617 administered before docetaxel.
Read More
Apalutamide vs Enzalutamide: Insights on Real-World Survival Benefits and Clinical Implications
Marc Greenstein, DO
mCSPC
|
October 31, 2024
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
View More
Assessing the ARANOTE Trial: Role of Darolutamide in Enhancing ADT for HSPC
Andrew Laccetti, MD, MS
nmHSPC
|
September 25, 2024
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
View More
Transformations in mPC: Risk Stratification, Therapy Approaches for Hormone-Sensitive Disease
Andrew Laccetti, MD, MS
mHSPC
|
September 25, 2024
Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing.
View More
Using rPFS, cPFS as Surrogate Primary End Points May Expedite mHSPC Trials
Emily Menendez
mHSPC
|
February 28, 2024
Phase III mHSPC trials can take up to a decade to complete when OS is used as the primary endpoint.
Read More
Low PNI May Indicate Poor Treatment Response in Patients With mHSPC Undergoing ADT
Emily Menendez
mCSPC
|
October 12, 2023
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
Read More
mHSPC With Suboptimal PSA Response Linked to Poor Survival Outcomes
Emily Menendez
mCSPC
|
October 12, 2023
Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.
Read More
How Does Performance Status Affect the Efficacy of Systemic Therapy for Prostate Cancer?
Emily Menendez
Prostate Cancer
|
October 12, 2023
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Read More
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
Emily Menendez
Prostate Cancer
|
October 12, 2023
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Read More
CHAARTED Trial Post Hoc Analysis Reveals QOL and Survival Outcomes
Emily Menendez
ASCO 2023
|
October 12, 2023
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Read More
Use of ARATs as First-line mHSPC Treatment Grows, NLR and PSA Serve as Prognostic Factors
Emily Menendez
mCSPC
|
October 12, 2023
Researchers studied several trials including LATITUDE and STAMPEDE to find similar characteristics among ARAT treatments.
Read More
Incidence of Clinical Fracture in mHSPC: Zoledronic Acid, Docetaxel, or Both?
Emily Menendez
AUA 2023
|
October 12, 2023
The STAMPEDE trial examined the addition of zoledronic acid, docetaxel, or both to ADT for the treatment of mHSPC.
Read More
Radiation’s Role in Metastatic Prostate Cancer Growing, Evolving
Leah Lawrence
Prostate Cancer
|
October 12, 2023
Several physicians highlight the newest data on radiation for metastatic prostate cancer and its role moving forward.
Read More
ENZAMET Trial OS Analysis: Testosterone Suppression Plus Enzalutamide or Antiandrogen Therapy
Emily Menendez
mCSPC
|
October 12, 2023
New research has reported updates on the primary OS analysis of the ENZAMET trial to define the benefit of enzalutamide.
Read More
Maha Hussain on the ARASENS Trial: Darolutamide Plus ADT, Docetaxel for mHSPC
Emily Menendez
Expert Interviews
|
October 12, 2023
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
Read More
Evaluating MDT Without ADT in Patients With Solitary Oligorecurrent Prostate Cancer
David Ambinder, MD
mCSPC
|
October 12, 2023
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
Read More
Assessing Utilization Patterns of mHSPC Treatment in a Community Oncology Practice Setting
Zachary Bessette
ASCO GU Symposium 2023
|
October 12, 2023
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Read More
Barriers to PARP Inhibitors Plus Androgen Receptor-Targeted Agents in Earlier Treatment Settings
Tanya Dorff, MD
mCSPC
|
October 12, 2023
Tanya Dorff, MD, shares the barriers to utilizing PARP inhibitors plus AR-targeted agents in early prostate cancer settings.
View More
The Future of Personalized Care in Oligometastatic Prostate Cancer
Matthew Deek, MD
mCSPC
|
October 12, 2023
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
View More
Load More
Advertisement
Advertisement
Advertisement